ORAMED PHARMACEUTICALS INC. Contract Liability (Deferred Revenue)
ORAMED PHARMACEUTICALS INC. (ORMP) had Contract Liability (Deferred Revenue) of $1.71 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-10
- 2026-06-30: Contract with Customer, Liability, Current $1.71M.
- 2026-03-31: Contract with Customer, Liability, Current $1.47M.
- 2025-12-31: Contract with Customer, Liability, Current $1.35M.
- 2019-05-31: Contract with Customer, Liability, Current $2.70M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $1.71M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $1.47M 10-Q · filed 2026-05-19 |
| 2025-12-31 | $1.35M 10-Q · filed 2026-08-10 |
| 2019-05-31 | $2.70M 10-Q · filed 2019-07-10 |
| 2019-02-28 | $2.70M 10-Q · filed 2019-04-10 |
| 2018-11-30 | $1.13M 10-Q · filed 2019-01-14 |
| 2018-08-31 | $2.45M 10-Q · filed 2019-07-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |